Navigation Links
Cepheid Reports Fourth Quarter And Full Year 2012 Results
Date:1/24/2013

SUNNYVALE, Calif., Jan. 24, 2013 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2012 of $92.4 million.  Net income was $5.6 million, or $0.08 per share, which compares to revenue of $80.1 million and net loss of $1.6 million, or $(0.03) per share, in the fourth quarter of 2011.  2011 fourth quarter results reflected a one-time, non-cash charge to cost of sales of $5.4 million, or $0.08 per share, associated with the termination of a patent license.

Excluding stock compensation expenses, impairment of intangible assets and licenses and amortization of acquired intangibles, non-GAAP net income for the fourth quarter of 2012 was $14.2 million, or $0.20 per share.  This compares to a non-GAAP net income of $9.4 million, or $0.14 per share, in the fourth quarter of 2011.

Fiscal 2012 OverviewFor the year ended December 31, 2012, Cepheid reported revenue of $331.2 million which compares to revenue of $277.6 million in 2011.  Net loss for the year was $20.0 million, or $(0.30) per share, which compares to net income of $2.6 million, or $0.04 per share, in 2011.  2012 full year net loss reflected a charge of $15.1 million, or $0.23 per share, associated with a litigation settlement.

Excluding stock compensation expenses, a litigation settlement charge, impairment of intangible assets and licenses, amortization of acquired intangibles and a tax benefit related to an intercompany intellectual property transaction, non-GAAP net income for the year was $21.8 million, or $0.31 per share.  This compares to a non-GAAP net income of $29.6 million, or $0.44 per share, for the full year 2011.

"2012 was a challenging year for Cepheid as we worked through growing pains associated with the scale-up of our manufacturing operations and adapted to the incremental variability associated with our
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ... delivery systems especially for type 1 diabetes ...
(Date:1/15/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ... the seller in cash, without interest (less any required ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire/ ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ... OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Trial to Examine Safety and Efficacy of DARA ... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced the initiation of a Phase 2b,clinical ... candidate.,This randomized, double-blind, placebo and active-controlled,parallel-group study is ...
... 29 A study reported in,the journal ... the,Ciliary Neurotrophic Factor gene (CNTF) may affect ... Vanda Pharmaceuticals,Inc., included patients with acute symptoms ... (iloperidone), a novel atypical,antipsychotic agent currently under ...
Cached Medicine Technology:Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 4Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... first time, researchers at the University of California, San Diego ... processes that power the celebrated health benefits of omega-3 fatty ... be possible to manipulate these processes to short-circuit inflammation before ... it becomes detrimental. The work is published in the ...
... in June,s Journal of Thoracic Oncology says molecular ... be an additional predictive technique for lung cancer screening. ... percent of the positive CT screening results were false positive, ... patients. This research focused on a way to determine if ...
... By Alan Mozes HealthDay Reporter , TUESDAY, May ... a silver bullet when it comes to symptom relief for ... analysis of six prior studies found that the sprays confer ... taken for three weeks at relatively high doses. The ...
... resident Maureen T. Kavanah, MD, an Associate Professor ... (BUSM) and a surgical oncologist at Boston Medical ... Surgical Adjuvant Breast and Bowel Project (NSABP) Distinguished ... and meritorious service to the NSABP in support ...
... for Idiopathic Toe Walking Based on Child,s Age and Severity ... walking pattern, or gait, by age 2. And while some ... the foot or toes, never touching the heel to the ... a neurological disorder. A review article, "Idiopathic Toe Walking," ...
... journal of the American Gastroenterological Association (AGA) Institute, are ... anticipated special 13th issue. Published each May, the 13th ... broad interest; this year,s topic is viral hepatitis. ... PhD, this issue was developed by Gastroenterology,s experts in ...
Cached Medicine News:Health News:Why omega-3 oils help at the cellular level 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 3Health News:Boston researcher, surgical oncologist receives national award 2Health News:Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights 2Health News:Gastroenterology special issue focuses on new directions of viral hepatitis care and research 2Health News:Gastroenterology special issue focuses on new directions of viral hepatitis care and research 3
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
500L...
... The new Finnpipette Focus from ... to combine ergonomics with uncompromising ... handle plate offers a custom ... The new shorter tip cones ...
Inquire...
Medicine Products: